Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-γ confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice

FEMS Immunology and Medical Microbiology

Volumn 51, Issue 3, 2007, Pages 480-487

  Xu, Ying ^a   Zhu, Bingdong ^a   Wang, Qingzhong ^a   Chen, Jiazhen ^a   Qie, Yaqing ^a   Wang, Jiuling ^a   Wang, Hongyan ^a   Wang, Baolin ^a   Wang, Honghai ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

IFN ; Mycobacterium tuberculosis; rBCG

Indexed keywords

ANTIGEN 85B; BACTERIAL ANTIGEN; BCG VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUBERCULOSIS;

ACYLTRANSFERASES; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; BODY WEIGHT; COLONY COUNT, MICROBIAL; FEMALE; INTERFERON TYPE II; LUNG; MICE; MICE, INBRED C57BL; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; RECOMBINANT FUSION PROTEINS; SPLEEN; T-LYMPHOCYTES; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, SYNTHETIC;

EID: 35948944602     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2007.00322.x     Document Type: Article

References (21)

1. Andersen P Doherty TM (2005) The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat Rev 3 : 656 662.
2. Arnold J, de Boer EC, O'Donnell MA, Bohle A Brandau S (2004) Immunotherapy of experimental bladder cancer with recombinant BCG expressing Interferon-gamma. J Immunotherapy 27 : 116 123.
3. Bao L, Chen W, Zhang HD Wang XY (2003) Virulence, immunogenicity, and protective efficacy of two recombinant Mycobacterium bovis bacillus calmette-Gue'rin strains expressing the antigen ESAT-6 from Mycobacterium tuberculosis. Infect Immun 71 : 1656 1661.
4. Bloom BR Fine PE (1994) The BCG experience: implications for future vaccines against tuberculosis. Tuberculosis: Pathogen Protect Control (Bloom BR, ed pp. 531 557. ASM Press, Washington, DC.
5. Brandt L, Elhay MJ, Rosenkrands I, Lindblad EB Andersen P (2000) ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 68 : 791 795.
6. Chan J, Xing Y, Magliozzo RS Bloom BR (1992) Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 175 : 1111 1122.
7. Dennehy M Williamson AL (2005) Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines. Vaccine 23 : 1209 1224.
8. Dye C, Scheele S, Dolin P, Pathania V Raviglione MC (1999) Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282 : 677 686.
9. Eddine AN Kaufmann SHE (2005) Improved protection by recombinant BCG. Microbes Infect 7 : 939 946.
10. Fine PEM (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346 : 1339 1345.
11. Horwitz MA, Harth G, Dillon BJ Maslesa-Galic' S (2000) Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30 kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 97 : 13853 13858.
12. Kaufmann SHE (2006) Envisioning future strategies for vaccination against tuberculosis. Nat Rev Immunol 6 : 699 704.
13. Langermans Jan AM, Doherty TM, Vervenne RAW et al 2005) Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23 : 2740 2750.
14. Luo Y, Chen X, Han R O'Donnell MA (2001) Recombinant bacilli Calmette-Guérin (BCG) expressing human interferon-a 2B demonstrates enhanced immunogenicity. Clin Exp Immunol 123 : 264 270.
15. Martin RM Lew AM (1998) Is IgG2a a good Th1 marker in mice? Immunol Today 19 : 49.
16. Murray PJ, Aldovini A Young RA (1996) Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc Natl Acad Sci USA 93 : 934 939.
17. Olsen AW, van Pinxteren LAH, Okkels LM, Rasmussen PB Andersen P (2001) Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Infect Immun 69 : 2773 2778.
18. Palendira U, Spratt JM, Britton WJ Triccas JA (2005) Expanding the antigenic repertoire of BCG improves protective efficacy against aerosol Mycobacterium tuberculosis infection. Vaccine 23 : 1680 1685.
19. Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A, Grifftths KE, Marchal G, Leclerc C Cole ST (2003) Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 9 : 533 539.
20. Stover CK, Bansal GP, Hanson MS, Burlein JE, Palaszynski SR, Young JF, Koenig S, Young DB, Sadziene A Barbour AG (1993) Protective immunity elicited by recombinant Bacille Calmette - Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J Exp Med 178 : 197 209.
21. Wangoo A, Brown IN, Marshall BG, Cook HT, Young DB Shaw RJ (2000) Bacille Calmette-Guerin (BCG)-associated inflammation and fibrosis: modulation by recombinant BCG expressing interferongamma (IFN-γ). Clin Exp Immunol 119 : 92 98.